thank all Nicole, and to you today. you, for time making join Thank us the
executing important During the on the of build strategic rare disease maintain strength. sustainable potential element disorders. a sleep company and position executing committee steady second our made building important to for of to of cash long-term for financial blocks flows. reliable the driving preparing launch plan advancing are quarter, our strategy build An meeting and strategic our with is against arimoclomol, the KPXXXX for progress advisory of objectives, launch our and we OLPRUVA These objectives
funding, momentum and as have bringing our offering forma right opportunities highlighting the following XXXX, confidence continue value our that this that $XXX.X and the to pro have we been and investments proceeds our June build near-term on our creation catalysts million outreach first significant into as sheet, cash, of There a undertook balance growing With we base of Committee million. of half added This the to objectives. execute our underwritten cash $XX.X demonstrate of XX, During company. approximately launch time FDA catalysts. the equivalents net a take to for to investor to sized public outcome momentum objectives, we meeting and made and flexibility this for our week, near- pipeline. our success. interest extend flexibility and proceeds as cash Advisory to Last both preparation in investors important prepare The including a modestly accelerate focused has favorable will long-term we a objective, of our runway lean our to primary the and and XXXX, of the executing potential capture arimoclomol we the arimoclomol, potential the clinical full step for on we was bolster
I'll share deliver remain summary we our optimistic second in a plan. to and key why ability our Now strategic of outline on quarter our accomplishments
arimoclomol. start with Let's
in Xnd, Committee, voted candidate the that C arimoclomol treatment On for Disease Advisory the August NPC. effective diseases NPC. genetic Type GMDC, product Our is or or favorably of metabolic Niemann-Pick
While the important FDA this we review. not factor its believe an the vote completes binding, is is as
U.S. working is the first Our would round NPC, treatment voucher. be last in of would We indicated be the is and first of approaching. arimoclomol the XXst, a closely PDUFA review approved, labeling and the fast it for If September received for Friday date comments FDA. eligible are drug priority which the with
Expanded in EAP. of U.S. the Program, those roughly with a X/X reminder, patients Access diagnosed treated. As in XXX enrolled our are people NPC, and approximately are of or are More than which there U.S. XX currently
we access patients supply for ensure is As to until EAP will commercial the the available. FDA continues, maintain review U.S.
where an to Europe, approval, U.S. to in XX global approval program. are enrolled patients we seek additional subsequent our addition, XX In will in EAP regulatory
the We for arimoclomol. are commercial preparing of launch actively
OLPRUVA often products the excellence, fit us was same optimize strategic the within arimoclomol. majority and centers teams Our with Both are targeted co-located that reach to address allowing commercial the with of to genetic built a of commercial infrastructure between prescribers multidisciplinary metabolic treatment infrastructure. diseases
when promoting as payers access rare for These with prelaunch disease raise potential has team pre-approval activities liaisons, specialists treatment a are are clinical who medical for Our science and urea-cycle awareness UCDs, also educating have market disorders, access our Further, NPC. discussions once regarding engaging patients with currently arimoclomol and OLPRUVA and ensure or to available. will NPC. initiated prescribers appropriate help
where OLPRUVA the we with January of to initiated turning at make to launch commercial process continue Now XXXX. the end
the assumption confirmed. OLPRUVA of few been our the quarters, on awareness has last Over limited
health with levels to providers and progress we work have identify increase awareness patient increase that made we've awareness. However, care to do to more
patients reminder, a U.S. receiving number in identified who from are benefit XXX than prescribing X,XXX treatment. has As which more there UCD these a significant patients are can the of OLPRUVA. community of The
their is encouraged the are number not response, we be. patient yet it by of like would we where enrollments While to
which During program a patient who is one X Quick paid we had or enrollments, the prescription quarter, on for dispense. Start as second our a define new we patient receiving who's a
patients, an ensure done team We of and team at has leaders HCPs brand remarkable awareness treat to have job market amongst since medical HCPs thought The build working has excellence engaging access been clinicians to become diagnose the The UCD has build challenging UCD successfully more treat access who for outstanding to to engaged at conferences industry. centers of the which of majority and who is target across and awareness. and patients. clinicians
continues team care managed to patients. our for payers access to ensure commercial broad and government engage with Additionally,
approve with have coverage status by plans formulary established designed community. health covered to patient rare of to with improved across increased care XX% the programs and the have experienced lives hurdles We services comprehensive reimbursement disease assist
revenue leader transition As solutions to our for launch, our a including This and always mid-June, impacted partner, on provide OLPRUVA a inventory was Orsini the support will improve in during LaDuane specialty more believe the call. for in our transition enhancements launch One we I mentioned pharmacy in quarter. sales the key changes opportunities our limited are details diseases. to have to there these the rare further a positive will in commercialization efforts channel, will OLPRUVA as pharmacy are of impact change in earlier, cost. net completed incremental infrastructure We refinement who arimoclomol later and our commercial our is which rebalance engagement. for patient with implementing
IH attention also disease daytime our your turn sleepiness approximately to This and or impacts inertia. characterized by the of like for a disorder. as people I'd idiopathic sleep the IH, XX,XXX U.S. KPXXXX, clinical candidate sleep treatment to rare is excessive chronic waking, known in difficulty hypersomnia, Now
active of most and substance ingredient. optimal dose you or data allows occurs was Enforcement sleep As unique may to during steadily methylphenidate, concentration receive designed is the XXXX inertia. dosing for abuse which the manage morning The SDX risk ensures morning a presented as Drug recall, potential. nighttime when by the waking meeting SERDx-mepylpenidate a flexible of showed is administered or due patients U.S. in currently lower for to Sleep At demonstrated it when peak to the in night. the profile Administration and these exposure the pharmacokinetic hours. we designated release patient clinical at Its SDX, SDX needs the the after June, primary drug pharmacokinetics overcome symptoms comprised to controlled IH its schedule
Adverse relatively products our daily. discontinuation. results which clinically positive of this Phase KPXXXX Sleepiness well included dose weeks secondary reported in treatment Scale, change the proof-of-concept at also levels, the symptoms and benefits events clinical high endpoints, the IH Analog scale were assess study fog. lead similar with new and We study, other and to notably Scale, showed patients Scale was II Sleep methylphenidate milligrams XXX baseline X all and IH. study to KPXXXX of dose of mild not Inertia exploratory in the from the change of end in the to early meaningful KPXXXX In Severity against tolerated at severity brain did Visual including the from of throughout Epworth a
KPXXXX tolerated We demonstrates well is showing these clinically and meaningful are by benefits. encouraged that results
an Importantly, the to and in a II to the of treatment, submitted for interpret leaders, help space X of only patient large have With consulted remains meeting advocates quarter. and key design the the efficacy payers trial. informing a We results third the objectives study the briefing rare unmet sleep the knowledgeable address FDA Phase pivotal FDA-approved successfully therapies these fulfilled a end of with of of to at opinion book IH. for the there end need symptoms
We market research the our are KPXXXX's inform understand data differentiated landscape profile to to better Phase and business the in on position case. treatment II conducting
AX ruptures. stress treatment collagen within connective and of of designed and wall Finally, EU vascular Celiprolol the significant has our muscle unmet and organ from mechanism need product for in and action we've vEDS, or address candidate treatments X,XXX made there believe treatment FDA. reduce Syndrome X on both approved celiprolol, and with which primary received are to arterial the Ehlers-Danlos hollow drug leads patients impairs no breakthrough therapy option mechanical U.S. through smooth orphan the the various the vascular Celiprolol the to for in call designations countries dilation the progress tissue is fibers Celiprolol's is relaxation. it the could with we as vEDS. vascular
trial known as of recruitment conducted being trial. the quarter, under is special assessment. trial, second decentralized the restarted DISCOVER protocol III we This the event-driven During Phase also a celiprolol
preserves We while which the community within among and our conduct are significant in to of encouraged we the the the our expectations, this program enroll has trial unmet portfolio by value review. need exceeded interest patients underscored beds the
the each programs. initiative the of January, to of of we part continue As assess off our kicked strategic planning in value
community case Our those to the address develop and develop disease how a a unmet understand rare therapies market for patient needs solid of to then clinical intent business and the potential needs. fully Zevra is can within
the to to arimoclomol II have we QX.
We built with of of ahead, for those a deliver pivotal KPXXXX and approval in well strong first, XXXX on of by infrastructure drive of successfully meeting to our end and third, the leveraging second are execute Looking end discuss for objectives. and evaluating OLPRUVA; focused the receive Second, efficacy the remain a launch execution financially patients against IH launch study design half to to priorities: OLPRUVA; in Phase of positioned at X the key
our financial on will results. update LaDuane provide an Now
